ValiRx PLC Posting of Annual Report and Notice of AGM (2395X)

TIDMVAL

RNS Number : 2395X

ValiRx PLC

30 April 2021

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Posting of Annual Report and Notice of AGM

AGM Arrangements During Pandemic

Q&A after AGM

London, UK, 30 April 2021: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces its Annual Report and Accounts for the year ended 31 December 2020 is available on the Company's website, www.valirx.com and will shortly be posted to relevant registered shareholders.

The Company also advises that the Notice of Annual General Meeting (the "Notice") and Form of Proxy are also available on the Company's website, www.valirx.com , and will shortly be posted to registered shareholders. The Annual General Meeting will be held at 11:00 am on 27 May 2021.

   -       COVID-19 restrictions 

Given the current Government advice on lockdown restrictions associated with the pandemic, the Company has determined that the resolutions to be voted at the AGM shall be voted on through a poll rather than on the show of hands. The Company believes this is the best and fairest way to ensure that the votes of all shareholders can be taken into account, whilst also preventing the Company and shareholders breaching applicable regulations. Accordingly, the Company strongly encourages all shareholders to either submit their proxy form or to use the CREST Proxy Voting Service, rather than attend the meeting in person in accordance with the Company's articles of association. Whilst completion and return of the proxy form or using the CREST Proxy Voting Service would not preclude shareholders from attending, speaking or voting in person at the AGM should they so wish, shareholders are reminded that to do so would potentially be in breach of UK Government regulations in relation to the containment and control of COVID-19.

   -       AGM quorum to be constituted by minimum quorum of director-shareholders 

The Board intends for the AGM to be held by a minimum quorum constituted by shareholders who are also directors, or their proxies, and shareholders are requested not to attend the AGM in person.

The latest date for receipt of proxies is Tuesday 25 May 2021 at 11am in accordance with the procedure set forth in the Notice. The result of the proxy votes will be announced after the AGM in the usual way.

   -       Live virtual Q&A 

In light of the inability to hold an in-person AGM for all shareholders, the Chairman and the CEO will be holding an online Q&A event for all shareholders at 1pm on 27 May 2021 after the closing of the AGM. Shareholders will be required to pre-register for this meeting and will be able to submit questions for a subsequent interactive discussion. Full details of how to register and access the event are available https://www.valirx.com/shareholder-communications.

*** ENDS ***

For more information, please contact:

 
 ValiRx plc                                   Tel: [phone] 
                                               www.valirx.com 
 Dr Suzy Dilly, Chief Executive               suzanne.dilly @valirx.com 
 
 Cairn Financial Advisers LLP (Nominated      Tel: [phone] 
  Adviser) 
  Liam Murray/Jo Turner/Ludovico Lazzaretti 
 Peterhouse Capital Limited (Sole Broker)     Tel: [phone] 
  Duncan Vasey/Lucy Williams/Eran Zucker 
 
 

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOADKKBKKBKDAQN

(END) Dow Jones Newswires

April 30, 2021 07:00 ET (11:00 GMT)